For the quarter ending 2025-09-30, PDSB has $34,705,801 in assets. $25,252,291 in debts. $26,198,652 in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 26,198,652 | 31,873,495 | ||
| Prepaid expenses and other assets | 1,694,258 | 1,774,550 | ||
| Total current assets | 27,892,910 | 33,648,045 | ||
| Prepaid expenses | 6,554,064 | 6,554,064 | ||
| Property and equipment, net | 125,643 | 131,102 | ||
| Financing lease right-to-use assets | 133,184 | 142,854 | ||
| Total assets | 34,705,801 | 40,476,065 | ||
| Accounts payable | 5,180,928 | 4,497,434 | ||
| Accrued expenses | 2,104,390 | 1,482,081 | ||
| Note payable - short term | 6,000,000 | 5,500,000 | ||
| Financing lease obligation-short term | 44,142 | 51,937 | ||
| Total current liabilities | 13,329,460 | 11,531,452 | ||
| Note payable, net of debt discount | 11,889,314 | 12,943,656 | ||
| Financing lease obligation-long term | 33,517 | 41,173 | ||
| Total liabilities | 25,252,291 | 24,516,281 | ||
| Common stock, 0.00033 par value, 150,000,000 shares authorized at september 30, 2025 and december 31, 2024, respectively 47,705,442 and 37,987,380 issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 15,744 | 15,390 | ||
| Additional paid-in capital | 218,481,351 | 215,978,568 | ||
| Accumulated deficit | -209,043,585 | -200,034,174 | ||
| Total stockholders' equity | 9,453,510 | 15,959,784 | ||
| Total liabilities and stockholders' equity | 34,705,801 | 40,476,065 | ||
PDS Biotechnology Corp (PDSB)
PDS Biotechnology Corp (PDSB)